Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Esophageal Neoplasms 1

Interventions

Fluorouracil 56Specimen Handling 51Oxaliplatin 49Leucovorin 46Magnetic Resonance Spectroscopy 45Bevacizumab 43Gemcitabine 39Irinotecan 30Cetuximab 27Nivolumab 25130-nm albumin-bound paclitaxel 25Cisplatin 24Biopsy 24pembrolizumab 22Paclitaxel 22Capecitabine 19atezolizumab 18durvalumab 14Taxes 14Folfox protocol 14Carboplatin 13X-Rays 12Radiotherapy 12Cyclophosphamide 12fludarabine 11dehydroftorafur 10Radiation 10Albumin-Bound Paclitaxel 10Surgical Procedures, Operative 9Immunoglobulin G 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Palonosetron × Gastrointestinal × 30 days × Clear all
NCT07617246 2026-06-01

The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
120 enrolled
GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡